Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 14/20 | 0.69 |
| ▸ | GRIN2B | Q13224 | 14/20 | 0.69 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.51 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.48 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19733248 | 1.00 | GRIN1 (0.69) | GRIN1GRIN2BCDK5CDK5R1NR1I3 | |
| SCHEMBL19253322 | 0.85 | GRIN1 (0.67) | GRIN1GRIN2BMAPK1GRIN2DGRIN2A | |
| SCHEMBL19253320 | 0.85 | GRIN1 (0.67) | GRIN1GRIN2BMAPK1GRIN2DGRIN2A | |
| SCHEMBL19253232 | 0.84 | GRIN1 (0.82) | GRIN1GRIN2BCDK5CDK5R1NR1I3 | |
| SCHEMBL19253162 | 0.84 | GRIN1 (0.82) | GRIN1GRIN2BCDK5CDK5R1NR1I3 | |
| SCHEMBL19253181 | 0.84 | GRIN1 (0.82) | GRIN1GRIN2BCDK5CDK5R1NR1I3 | |
| SCHEMBL19733259 | 0.84 | GRIN1 (0.82) | GRIN1GRIN2BCDK5CDK5R1NR1I3 | |
| SCHEMBL2436612 | 0.83 | MAPK1 (0.74) | GRIN1GRIN2BMAPK1 | |
| SCHEMBL16345488 | 0.83 | MAPK1 (0.74) | GRIN1GRIN2BMAPK1 | |
| SCHEMBL2435124 | 0.83 | MAPK1 (0.74) | GRIN1GRIN2BMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3186267-B1 | AMPHIPHILIC COMPOUNDS WITH NEUROPROTECTIVE PROPERTIES | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) | 2019-10-02 | — | — | EP | disclosed |
| US-10017535-B2 | Amphiphilic compounds with neuroprotective properties | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2018-07-10 | — | — | US | disclosed |
| US-20170240588-A1 | AMPHIPHILIC COMPOUNDS WITH NEUROPROTECTIVE PROPERTIES | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240588-A1 | AMPHIPHILIC COMPOUNDS WITH NEUROPROTECTIVE PROPERTIES | GAP43, GRIN2A, GRIN3A | GRIN1 14/4885GRIN2B 8/4885CDK5 2779/4885 |
| US-10017535-B2 | Amphiphilic compounds with neuroprotective properties | GAP43, GRIN2A, GRIN3A | GRIN1 14/4885GRIN2B 8/4885CDK5 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.